“Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naive T Cells from Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201”, J Clin Oncol, vol. 32, pp. 2365-2372, 2014.,
“Recommendations for Donor Human Leukocyte Antigen Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)”, Biol Blood Marrow Transplant, vol. 21, no. 1, pp. 4-7, 2014.
“Characteristics of CliniMACS® System CD34-Enriched T Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303”, Biol Blood Marrow Transplant, vol. 18, pp. 690-697, 2012.,
“A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results from CALGB 100103/BMT CTN 0502”, in 54th Annual ASH Meeting, Atlanta, GA, 2012.,
“Alternative Donor Transplantation: Results of Parallel Phase II Trials Using HLA-Mismatched Related Bone Marrow or Unrelated Umbilical Cord Blood Grafts”, Blood, vol. 118, no. 2, pp. 282-288, 2011.